The clock keeps ticking for intravenous methylprednisolone

Bergh, Florian Then
August 2007
Journal of Neurology, Neurosurgery & Psychiatry;Aug2007, Vol. 78 Issue 8, p788
Academic Journal
The author reflects on the research conducted by Glass-Marmor and colleagues on patients with multiple sclerosis in acute relapse to receive intravenous methylprednisolone (MP). He cited the result of the study that plasma level of endogenous cortisol and their impact on immune function are lowest in the evening, and therapeutic effects my be particularly pronounced on surroundings. He suggested that further study for the improvement of multiple sclerosis treatments should be conducted.


Related Articles

  • High-dose intravenous immunoglobulin treatment of multiple sclerosis. Durelli, L.; Isoardo, G. // Neurological Sciences;Apr2002 Supplement 1, Vol. 23, pS39 

    A review of the pathological basis of multiple sclerosis is presented to see whether the many immunological effects if IVIg may exert some benefit and at what level. This is probably due to the wide spectrum of interactions between IVIg and the immune system, which are analyzed in this review....

  • let me tell you…about my shots, Tennessee style. Clem, Jeanne // Inside MS;Oct/Nov2006, Vol. 24 Issue 5, p66 

    The article discusses the author's experience dealing with her multiple sclerosis (MS). She mentioned the conflict she had with insurance companies in relation to her medical treatment. She described the challenges she face when administering injection for her MS. She also said things about...

  • IV Immunoglobulin Delays Onset of Multiple Sclerosis. Barry, Henry // American Family Physician;2/15/2005, Vol. 71 Issue 4, p785 

    Discusses research being done on the effect of intravenous immunoglobulin treatment on the development of multiple sclerosis following an initial neurologic event associated with demyelination. Reference to a study by A. Achiron et al published in the October 2004 issue of "Archives of...

  • A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS).  // Health & Quality of Life Outcomes;2011, Vol. 9 Issue 1, p80 

    The article presents a study which examines the role of Multiple Sclerosis Relapse Management Scale (MSRMS) in patients with multiple sclerosis (MS). It reveals that the MSRMS is a reliable and valid measure for MS relapse management in patients. It concludes that MSRMS is a powerful tool to...

  • Feasibility investigation of allogeneic endometrial regenerative cells. Zhaohui Zhong; Patel, Amit N.; Ichim, Thomas E.; Riordan, Neil H.; Hao Wang; Wei-Ping Min; Woods, Erik J.; Reid, Michael; Mansilla, Eduardo; Marin, Gustavo H.; Drago, Hugo; Murphy, Michael P.; Minev, Boris // Journal of Translational Medicine;2009, Vol. 7, p1 

    Endometrial Regenerative Cells (ERC) are a population of mesenchymal-like stem cells having pluripotent differentiation activity and ability to induce neoangiogenesis. In vitro and animal studies suggest ERC are immune privileged and in certain situations actively suppress ongoing immune...

  • Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Pöhlau, D.; Przuntek, H.; Sailer, M.; Bethke, F.; Koehler, J.; König, N.; Heesen, C.; Späth, P.; Andresen, I. // Multiple Sclerosis (13524585);Nov2007, Vol. 13 Issue 9, p1107 

    In patients with relapsing-remitting multiple sclerosis (MS), IVIG was shown to reduce the relapse rate and progression of disability. In patients with chronic progressive MS, a beneficial effect of IVIG was not documented in placebo controlled studies. This trial investigated the influence of...

  • Effectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis. Marchioni, E.; Marinou-Aktipi, K.; Uggetti, C.; Bottanelli, M.; Pichiecchio, A.; Soragna, D.; Piccolo, G.; Imbesi, F.; Romani, A.; Ceroni, M. // Journal of Neurology;Jan2002, Vol. 249 Issue 1, p100 

    Randomized Controlled Trials have not jet established the best pharmacological management of Acute Disseminated Encephalomyelitis (ADEM). High dose steroids are usually employed with good results, but in a few cases the clinical outcome is poor. In other patients, particularly those affected by...

  • Monthly corticosteroids decrease neutralizing antibodies to IFNβ1b: a randomized trial in multiple sclerosis. Pozzilli, Carlo; Antonini, Giovanni; Bagnato, Francesca; Mainero, Caterina; Tomassini, Valentina; Onesti, Emanuela; Fantozzi, Roberta; Galgani, Simona; Pasqualetti, Patrizio; Millefiorini, Enrico; Spadaro, Maria; Dahlke, Frank; Gasperini, Claudio // Journal of Neurology;Jan2002, Vol. 249 Issue 1, p50 

    Neutralizing antibodies (NAB) to interferon beta (IFNβ) occur in some multiple sclerosis (MS) patients, particularly during the first year of treatment. The presence of NAB may be associated with an attenuation of the therapeutic effect. The aim of this study was to compare the frequency of...

  • Alemtuzumab: a guide to its use in relapsing-remitting multiple sclerosis. Keating, Gillian; Garnock-Jones, Karly // Drugs & Therapy Perspectives;Oct2014, Vol. 30 Issue 10, p337 

    The humanized monoclonal antibody alemtuzumab (Lemtradaâ„¢) is a welcome addition to the available treatment options for adults with active relapsing-remitting multiple sclerosis (RRMS) in the EU. It has a highly convenient administration regimen comprising two short courses of intravenous...


Read the Article


Sign out of this library

Other Topics